Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma
- 15 August 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (16), 3212-3214
- https://doi.org/10.1200/jco.2004.05.984
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple MyelomaJournal of Clinical Oncology, 2004
- Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological ActivityMayo Clinic Proceedings, 2004
- The evolution of thalidomide and its IMiD derivatives as anticancer agentsNature Reviews Cancer, 2004
- Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivoLeukemia, 2003
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Molecular mechanisms of novel therapeutic approaches for multiple myelomaNature Reviews Cancer, 2002
- Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed MyelomaJournal of Clinical Oncology, 2002
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Advances in disease biology: Therapeutic implicationsSeminars in Hematology, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999